Sign in

www.GastroToday.com

@gastrotoday.bsky.social
9 followers 18 following 64 posts

GastroToday.com features breaking news, commentary, and updates to inform healthcare professionals on the latest research and best clinical practices in gastroenterology | www.GastroToday.com

PostsRepliesMedia
www.GastroToday.com @gastrotoday.bsky.social · 01/10/2026
According to a retrospective cohort study by Elizabeth Spencer at Mount Sinai, #upadacitinib can be considered an effective maintenance treatment for pediatric patients with refractory #CrohnDisease. #PediatricCrohnsDisease #PediatricIBD #IBDSky #GISky www.docwirenews.com/post/real-wo...
docwirenews.com
Upadacitinib Maintenance for Pediatric CD | Gastro Today
Real-world data showed that upadacitinib is effective maintenance therapy for pediatric Crohn’s disease.
000
www.GastroToday.com @gastrotoday.bsky.social · 19/09/2026
Family history of #ColorectalCancer increased the risk of #CRC similarly between patients with #IBD and the general population. Those with multiple relatives with CRC showed the highest increase in CRC risk. #IBDSky #GISky #GIOnc www.docwirenews.com/post/family-...
docwirenews.com
How Does Family History of CRC Impact Risk for Patients With IBD? | Gastro Today
In a cohort study, patients with IBD and multiple family members with CRC were found to have the most increased risk of CRC.
000
www.GastroToday.com @gastrotoday.bsky.social · 17/09/2026
In a phase 2a study, THR-β agonist #ALG-055009 reduced liver fat in patients with #MASH. Study lead Dr. Loomba commented that these results support further studies evaluating “longer durations of ALG-055009 and its effect on liver histology.” #LiverSky www.docwirenews.com/post/investi...
docwirenews.com
ALG-055009 Shows Promise in MASH | Docwire News
In a phase 2a study, ALG-055009, a THR-β agonist, reduced liver fat for patients with metabolic dysfunction-associated steatohepatitis.
000
www.GastroToday.com @gastrotoday.bsky.social · 11/09/2026
A study from Mazen Noureddin, MD, (of @houstonmethodistmd.bsky.social), found that 11% of patients screened for #MASLD clinical trials had PEth results of ≥20 ng/mL, indicating a potential need for further clinical evaluation for possible #MetALD or #ALD. www.docwirenews.com/post/phospha...
docwirenews.com
Using Phosphatidylethanol to Rule Out MetALD/ALD | Docwire News
Among patients screened for MASLD clinical trials, 11% had PEth results that could indicate the potential for MetALD or ALD.
001
www.GastroToday.com @gastrotoday.bsky.social · 10/09/2026
Is heat-not-burn #tobacco safer in #CrohnsDisease? A retrospective study found the use of #HNBT products was associated with increased risk of postoperative endoscopic recurrence of Crohn’s disease when compared with nonsmoking. #GI #IBDSky www.docwirenews.com/post/impact-...
docwirenews.com
Is Heat-Not-Burn Tobacco Safer in Crohn’s Disease? | Docwire News
According to a retrospective study, the use of heat-not-burn tobacco products was associated with increased risk of postoperative endoscopic recurrence of Crohn’s disease.
000
www.GastroToday.com @gastrotoday.bsky.social · 05/09/2026
A meta-analysis and systemic review from @dranuraagj.bsky.social found JAK inhibitors to be "promising and effective options" for patients with acute severe #UlcerativeColitis as adjunct therapy to corticosteroids and rescue therapy. #ASUC #GISky #IBDSky www.docwirenews.com/post/jak-inh...
docwirenews.com
JAK Inhibitors Promising for ASUC Management | Docwire News
A systematic review and meta-analysis found Janus kinase (JAK) inhibitors safe and effective for patients with acute severe ulcerative colitis.
000
www.GastroToday.com @gastrotoday.bsky.social · 31/08/2026
Dr Elliot Tapper from @umich.edu shares some innovative potential treatment options for #BileAcidDiarrhea - and the joys that come from clinical investigation. #GISky 🌟 Read the full article here: www.docwirenews.com/post/bile-ac...
docwirenews.com
Drug Repurposing in Bile Acid Diarrhea | Docwire News
Gastro Today Editorial Board Member, Dr. Elliot Tapper discusses the treatment options for bile acid diarrhea through a series of clinical investigations.
000
www.GastroToday.com @gastrotoday.bsky.social · 29/08/2026
Patients with #InflammatoryBowelDisease have an increased risk of psychiatric disorder from 2-3 years before diagnosis through 10 years after, highlighting the need for integration of psych. care into #IBD management. #GISky #IBDSky 🌟 Read the full article: www.docwirenews.com/post/inflamm...
docwirenews.com
When Are Psychiatric Comorbidities in IBD Most Likely to Occur? | Docwire News
A cohort study of Swedish patients with inflammatory bowel disease found an increased risk of any psychiatric disorder from 2 to 3 years before diagnosis through 10 years after.
000
www.GastroToday.com @gastrotoday.bsky.social · 27/08/2026
An investigational glucagon/GLP-1 dual agonist reduced liver fat compared with placebo among patients with #MASLD and #MASH. Dr. Noureddin (@houstonmethodistmd.bsky.social) said these results support further evaluation of DD01 in long-term studies. #LiverSky www.docwirenews.com/post/investi...
docwirenews.com
DD01 Improved Liver Fat in MASH, MASLD | Docwire News
In a phase 2 trial, investigational glucagon and GLP-1 receptor dual agonist, DD01, showed reductions in liver fat compared with placebo among patients with MASLD and MASH.
011
www.GastroToday.com @gastrotoday.bsky.social · 06/08/2026
Adam Faye, MD, of NYU Langone Health, discusses the safety of #guselkumab among older patients with immune-mediated inflammatory diseases, such as #InflammatoryBowelDisease, #Psoriasis, and #PsoriaticArthritis. #IBDSky #GISky 📹 Watch the full interview here: www.docwirenews.com/post/the-imp...
docwirenews.com
Balancing Disease Control and Safety for Older Adults With IBD | Docwire News
Adam Faye, MD, shares results from a study evaluating the safety of guselkumab among older populations of patients with immune-mediated inflammatory diseases.
000
www.GastroToday.com @gastrotoday.bsky.social · 31/07/2026
Sigh Pichamol Jirapinyo, MD, from Brigham and Women's, discusses the potential of endoscopic bariatric therapies for patients with #MetALD, an etiology of #LiverDisease with growing incidence and limited treatments. #LiverSky 📹 Watch the full interview here: www.docwirenews.com/post/endosco...
docwirenews.com
Endoscopic Bariatric Therapy for MetALD | Docwire News
Sigh Pichamol Jirapinyo, MD, discusses results from a study evaluating endoscopic bariatric therapies as a potential treatment for MetALD.
001
www.GastroToday.com @gastrotoday.bsky.social · 30/07/2026
Mohammad Alabbas, MD, from @clevelandclinic.bsky.social, discusses the impact of psychologic comorbidities at the time of diagnosis of #EosinophilicEsophagitis. #EoE #GISky 📹 Watch the full interview here: www.docwirenews.com/post/outcome...
docwirenews.com
The Impact of Psychologic Comorbidities on EoE Outcomes | Docwire News
Dr. Alabbas discusses the impact of psychologic comorbidities at the time of diagnosis of eosinophilic esophagitis.
000
www.GastroToday.com @gastrotoday.bsky.social · 27/07/2026
Jeffrey Hyams, MD, discusses #ustekinumab for pediatric patients with #UlcerativeColitis who had conventional therapies. With the UNIFI JR results, ustekinumab may be "a very attractive therapy" for these patients. #GISky #IBDSky 📹 Watch the full interview here: www.docwirenews.com/post/ustekin...
docwirenews.com
Ustekinumab May Fill Unmet Need for Pediatric Ulcerative Colitis | Docwire News
Jeffrey Hyams, MD, shares results from the UNIFI JR trial, evaluating ustekinumab for pediatric patients with ulcerative colitis who had received conventional therapies.
000
www.GastroToday.com @gastrotoday.bsky.social · 21/07/2026
Corey Siegel, MD, from @dartmouthhealth.bsky.social, discusses the #RADIUSProgram which pairs a large specialty care center with small community-based practices to ensure no #IBD patient falls through the cracks. #GISky #IBDSky 📹 Watch the full interview here: www.docwirenews.com/post/expandi...
docwirenews.com
Bringing IBD Specialty Care to Rural Regions | Docwire News
Corey Siegel, MD, discusses the RADIUS program, which pairs larger specialty centers with smaller rural practices to jointly oversee the care of patients with IBD.
020
www.GastroToday.com @gastrotoday.bsky.social · 18/07/2026
Don't miss Dr Elliot Tapper's (@ebtapper.bsky.social) review of "The Liver Doctor" by Dr Cyriac Abby Phillips. Dr Tapper calls this book, "both a compelling work of medical narrative and a quiet act of advocacy." #LiverSky #TheLiverDoc Read the full review here: www.docwirenews.com/post/bringin...
docwirenews.com
The Liver Doctor: A Compelling Work of Medical Narrative and Advocacy | Docwire News
Gastro Today Editorial Board member, Elliot Tapper, MD, offers a review of The Liver Doctor by Dr. Cyriac Abby Phillips.
000
www.GastroToday.com @gastrotoday.bsky.social · 16/07/2026
Corey Ketchem, MD, of @feinberg.northwestern.edu, shares the results of a study correlating I-SEE score with FLIP metrics for #EosinophilicEsophagitis. #GISky #EoE 📹 Watch our full interview here: www.docwirenews.com/post/i-see-a...
docwirenews.com
Correlation of I-SEE and FLIP metrics | Docwire News
Corey Ketchem, MD, discusses a study that found more advanced mechanical impairments of the esophagus, as seen via FLIP, correlated with worse I-SEE score.
000
www.GastroToday.com @gastrotoday.bsky.social · 13/07/2026
Christopher Ma, MD, of @ucalgary.bsky.social, discusses results from the RESOLVE trial, evaluating #EP104GI, an injectable formulation of the steroid fluticasone, for treatment of #EosinophilicEsophagitis. #GISky 📹 Watch the full interview with Dr Ma here: www.docwirenews.com/post/injecta...
docwirenews.com
Injectable Steroid for EoE | Docwire News
In the phase 1b/2 RESOLVE study, EP-104GI, an injectable formulation of the steroid fluticasone, showed promise in the treatment of eosinophilic esophagitis.
000
www.GastroToday.com @gastrotoday.bsky.social · 06/07/2026
Kathleen Ferrell, PA-C, MPAS, from UNC Chapel Hill discusses the important role a #PhysicianAssistant plays when diagnosing, treating, and managing patients with #EosinophilicEsophagitis. #GISky #EoE 📹 Get the APP Perspective in the full interview: www.docwirenews.com/post/the-phy...
docwirenews.com
The PA’s Role in Eosinophilic Esophagitis | Docwire News
Kathleen Ferrell, PA-C, MPAS, discusses the important role a physician assistant plays when managing patients with eosinophilic esophagitis.
000
www.GastroToday.com @gastrotoday.bsky.social · 02/07/2026
Maarten Pruijt, MD, from Amsterdam University Medical Center, shares data on #IntestinalUltrasound and #FecalCalprotectin as a predictor of remission after ileocecal resection for #CrohnsDisease. #GISky #IBDSky 📹 Watch the full interview here: www.docwirenews.com/post/non-inv...
docwirenews.com
Intestinal Ultrasound Plus Fecal Calprotectin Predicts Crohn’s Recurrence | Docwire News
Maarten Pruijt, MD, shares results from the INSIGHT study, evaluating intestinal ultrasound and fecal calprotectin to predict 6-month remission after ileocecal resection for CD.
000
www.GastroToday.com @gastrotoday.bsky.social · 29/06/2026
We spoke with Dhyanesh Patel, MD, of @vanderbilt.edu, about a study evaluating the ability of a mucosal integrity testing device to identify #EoE during an endoscope procedure. #EosinophilicEsophagitis #GISky 📹 Watch the full interview here: www.docwirenews.com/post/mucosal...
docwirenews.com
Mucosal Integrity Testing for EoE | Docwire News
Dhyanesh Patel, MD, discusses a mucosal integrity testing device that was able to identify eosinophilic esophagitis and disease severity during endoscopy.
000
www.GastroToday.com @gastrotoday.bsky.social · 27/06/2026
Don't miss our interview with Edward Loftus, Jr, MD, of @mayoclinic.org, shares insights on the anti–IL-23 targeted oral peptide, #icotrokinra, in #UlcerativeColitis. #IBDSky #GISky 📹 Check out the full interview: www.docwirenews.com/post/icotrok...
100
www.GastroToday.com @gastrotoday.bsky.social · 25/06/2026
Don't miss Prateek Sharma, MD, @universityofkansas.bsky.social, sharing insights on the results from the #REMODEL trial which found #dupilumab improved esophageal distensibility in #EosinophilicEsophagitis. #GISky #EoE 📹 Watch the full interview: www.docwirenews.com/post/added-b...
docwirenews.com
Dupilumab in EoE | Docwire News
Prateek Sharma, MD, provides commentary on the data from the REMODEL study, evaluating the effect of dupilumab on esophageal distensibility in eosinophilic esophagitis.
000
www.GastroToday.com @gastrotoday.bsky.social · 22/06/2026
In the duplicate phase 3 B-Well trials, #bepirovirsen, an antisense oligonucleotide targeting #HepatitisBVirus transcripts, led to a functional cure among patients with chronic #HBV infection who discontinued nucleoside or nucleotide analogue (NA) therapy. www.docwirenews.com/post/bepirov...
docwirenews.com
On the Precipice of a Cure for HBV Infection | Docwire News
In two duplicate phase 3 trials, bepirovirsen led to a functional cure among patients with chronic HBV infection after discontinuing nucleoside or nucleotide analogue therapy.
000
www.GastroToday.com @gastrotoday.bsky.social · 20/06/2026
At #DDW26, Charanpreet Sasan, of @umasschan.bsky.social, spoke on #GLP1 receptor agonists as a treatment for #MASH #cirrhosis compared to #MetabolicBariatricSurgery. #GISky #LiverSky 📹 Watch the full interview here: www.docwirenews.com/post/glp-1-r...
docwirenews.com
GLP-1 Receptor Agonists for Cirrhosis | Docwire News
Charanpreet Sasan, MD, shares results comparing GLP-1 receptor agonists and metabolic-bariatric surgery for cirrhosis.
010
www.GastroToday.com @gastrotoday.bsky.social · 18/06/2026
At #DDW2026, we got an update to the #NordICC trial. Michael Bretthauer, from @uio.no, spoke to us about the data, concluding, "Screening or not, it doesn't do much for your death risk, but that risk is very, very low." 📹 Watch the full interview: www.docwirenews.com/post/effect-...
docwirenews.com
13-Year Data From the NordICC Trial | Docwire News
Michael Bretthauer, MD, shares an update from the NordICC trial, evaluating colonoscopy for colon cancer incidence and mortality, with 13 years of follow-up.
020
www.GastroToday.com @gastrotoday.bsky.social · 12/06/2026
Christopher Ma, MD, of University of Calgary, shares results from the phase 2 ARTEMIS-UC trial, evaluating #tulisokibart for patients with moderately to severely active #UlcerativeColitis. #GISky #IBDSky 📹 Watch the full interview here: www.docwirenews.com/post/tulisok...
docwirenews.com
Sustained Results With Tulisokibart for UC | Docwire News
Christopher Ma, MD, shares results from the phase 2 ARTEMIS-UC trial, evaluating tulisokibart, a TL1A monoclonal antibody, for moderately to severely active ulcerative colitis.
000
www.GastroToday.com @gastrotoday.bsky.social · 09/06/2026
Uma Mahadevan, MD, from @ucsfhealth.bsky.social, discusses the delicate balance between drug safety and disease control for pregnant patients taking #JAKInhibitors for #IBD. #GISky #PregnancyCare #IBDSky 📹 Watch the full interview: www.docwirenews.com/post/birth-d...
docwirenews.com
Balancing Drug Safety and Disease Control in Pregnant Patients With IBD | Docwire News
Uma Mahadevan, MD, shares data on the risk for birth defects when JAK inhibitors are used during pregnancy for patients with inflammatory bowel disease.
000
www.GastroToday.com @gastrotoday.bsky.social · 05/06/2026
What increases healthcare resource utilization among patients with #IBS-C? Kyle Staller, MD, MPH, from @harvardmed.bsky.social , discussed some of the causes at #DDW2026. #GISky #IrritableBowelSyndrome #Constipation 📹 Check out the full interview: www.docwirenews.com/post/medicat...
docwirenews.com
What Increases Healthcare Resource Utilization in IBS-C? | Docwire News
Kyle Staller, MD, MPH, discusses how medication switching may lead to increased healthcare resource utilization among patients with irritable bowel syndrome with constipation.
000
www.GastroToday.com @gastrotoday.bsky.social · 04/06/2026
David Lieberman, from @ohsunews.bsky.social, comments on the #NordICC update on #colonoscopy to prevent #ColonCancer that was presented at #DDW2026. #GISky 📹 Watch the full interview here: www.docwirenews.com/post/updated...
docwirenews.com
An Update From the NORDICC Trial | Docwire News
David Lieberman, MD, comments on the updated data from the NORDICC trial.
000
www.GastroToday.com @gastrotoday.bsky.social · 28/05/2026
Elliot Tapper, MD, (@ebtapper.bsky.social), from University of Michigan, highlights three non-IBD abstracts from #DDW2026, touching on cirrhosis, pancreatitis, and reflux. #Gastroenterology 📹 Watch the full report from Dr. Tapper: www.docwirenews.com/post/best-of...
docwirenews.com
Best of Pancreas, Swallowing, and Liver at DDW | Docwire News
Elliot Tapper, MD, highlights several abstracts being presented at Digestive Disease Week 2026 in the field of pancreatitis, reflux, and liver.
000
www.GastroToday.com @gastrotoday.bsky.social · 25/05/2026
Stephen Hanauer, MD, from @feinberg.northwestern.edu, shares his Big 3 Takeaways for #IBD from #DDW2026: early effective treatment, the shift toward oral agents, and combination therapies. #GISky #IBDSky 📹 Don't miss the full interview: www.docwirenews.com/post/digesti...
docwirenews.com
DDW 2026: 3 Big IBD Takeaways | Docwire News
Stephen Hanauer, MD, shares three main takeaways in inflammatory bowel disease from this year’s Digestive Disease Week.
010
www.GastroToday.com @gastrotoday.bsky.social · 22/05/2026
We spoke with Nurulamin Noor, of@cuh.nhs.uk, at #DDW2026 about the PROFILE study, which found that early effective top-down therapy from the point of diagnosis appears to modify the course of #CrohnsDisease. #GISky #IBDSky 📹 Watch the full interview here: www.docwirenews.com/post/earlier...
docwirenews.com
“Top-Down” Therapy for Crohn’s Disease | Docwire News
Nurulamin Noor, MD, PhD, discusses 4-year data from the PROFILE study, evaluating “top-down” therapy for patients with Crohn’s disease, as compared with the “step-up" approach.
000
www.GastroToday.com @gastrotoday.bsky.social · 21/05/2026
At #DDW2026, Anouk Overdevest, of @amsterdamumc.bsky.social, shared data from the COBRA trial, evaluating a one-day course of #antibiotics following biliary drainage for #cholangitis. #GISky 📹 Watch our full interview with Dr Overdevest while onsite at DDW: www.docwirenews.com/post/one-day...
docwirenews.com
Reduction of Antibiotic Course After Biliary Drainage | Docwire News
Anouk Overdevest, MD, shares data on 1 day of antibiotics vs 4-to-7 days after biliary drainage for acute cholangitis.
011
www.GastroToday.com @gastrotoday.bsky.social · 23/04/2026
Subcutaneous #infliximab maintenance demonstrated consistent clinical and endoscopic efficacy across #CrohnsDisease locations. Read more insights on #LIBERTYCD trial from Dr Colombel, of Icahn School of Medicine. #GISky #IBDSky www.docwirenews.com/post/subcuta...
docwirenews.com
Subcutaneous Infliximab for CD by Location | Docwire News
Subcutaneous infliximab in maintenance showed consistent clinical, endoscopic efficacy across Crohn’s disease locations, including the terminal ileum.
000
www.GastroToday.com @gastrotoday.bsky.social · 22/04/2026
🌟 Dr Tapper (@ebtapper.bsky.social) comments on a recent study which found #MASLD has surpassed #HepatitisCVirus as the leading cause of #cirrhosis among US #veterans. #Gastroenterology #Hepatology www.docwirenews.com/post/the-cha...
docwirenews.com
Shifts in Cirrhosis Causes | Docwire News
Metabolic dysfunction-associated steatotic liver disease now leads as the cause of cirrhosis, passing hepatitis C, among US veterans.
000
www.GastroToday.com @gastrotoday.bsky.social · 17/04/2026
The risk for mild infections, particularly viral infections, was found to increase with use of #thiopurines to treat patients with #InflammatoryBowelDisease; however, the risk for moderate-to-severe infections was not increased. #IBDSky #GISky www.docwirenews.com/post/thiopur...
docwirenews.com
Thiopurines and Infection in IBD | Docwire News
Thiopurine use for IBD was associated with an increased risk for mild infections.
000
www.GastroToday.com @gastrotoday.bsky.social · 30/03/2026
Don't miss the commentary from @ebtapper.bsky.social on #FecalMicrobiotaTransplantation for liver disease. Dr Tapper isn't sure that we're ready to "claim victory" with #FMT just yet. #Hepatology #GISky #LiverSky Read the full commentary at the link:
docwirenews.com
Fecal Microbiota Transplantation for Liver Disease | Docwire News
Dr Tapper, Gastro Today Editorial Board Member, shares his insights into the use of fecal microbiota transplantation for liver disease.
000
www.GastroToday.com @gastrotoday.bsky.social · 26/03/2026
Professor Laurent Peyrin-Biroulet discusses a study evaluating use of the Iterative Health site network to improve enrollment for #InflammatoryBowelDisease trials. #IBDSky #GISky 📹 Watch the full interview at the link! www.docwirenews.com/post/improvi...
docwirenews.com
Site Network for IBD Trials | Docwire News
Laurent Peyrin-Biroulet, MD, PhD, describes the results of a study evaluating use of a site network to improve enrollment for IBD trials.
000
www.GastroToday.com @gastrotoday.bsky.social · 10/03/2026
In a large real-world study, more than 60% of patients with #CrohnsDisease treated with #risankizumab achieved steroid-free clinical remission by week 12, and through 1 year of treatment. #Gastroenterology #GISky #inflammatoryBowelDisease #IBDSky
docwirenews.com
Risankizumab for Heavily Pretreated CD | Docwire News
Real-world data showed 60% of patients with heavily pretreated Crohn’s disease who received risankizumab achieved steroid-free clinical remission by week 12.
010
www.GastroToday.com @gastrotoday.bsky.social · 06/03/2026
Colonic delivery of #FecalMicrobiotaTransplantation was a more effective route than nasogastric administration for patients with #UlcerativeColitis. #Gastroenterology #InflammatoryBowelDisease #IBDSky #GISky #FMT
docwirenews.com
Delivery Route of FMT: Colonic vs Nasogastric | Docwire News
Colonic delivery of fecal microbiota transplantation was a more effective route than nasogastric administration for patients with ulcerative colitis.
010
www.GastroToday.com @gastrotoday.bsky.social · 05/03/2026
Researchers used machine learning to identify subgroups of patients with unresectable #HepatocellularCarcinoma treated with #atezolizumab and #bevacizumab with different patterns of progression and prognostic trajectories. #HCC #hepatology #oncology
docwirenews.com
HCC Subgroups May Guide Personalized Treatment, Patient Selection | Docwire News
Machine learning-identified subgroups of patients with unresectable HCC treated with atezo-bev may help guide personalized treatment strategies and patient selection.
020
www.GastroToday.com @gastrotoday.bsky.social · 02/03/2026
There is a need for equity in #ColorectalCancer screening for #LGBTQIA+ individuals. Vidhi Singh from David Geffen School of Medicine at UCLA describes the specific barriers that affect this population. #CRC #CancerScreening #CancerPrevention #Oncology
docwirenews.com
CRC Screening Uptake in LGBTQIA+ Individuals | Docwire News
Vidhi Singh discusses the need for equity in colorectal cancer (CRC) screening for LGBTQIA+ individuals.
010
www.GastroToday.com @gastrotoday.bsky.social · 20/02/2026
Taryn Lores, PhD, of the Icahn School of Medicine at Mount Sinai, discusses integrating #BehavioralIntervention therapy into treatment for patients with #CrohnsDisease. #IBDSky #GISky
docwirenews.com
Behavioral Interventions for Crohn’s Disease | Docwire News
Taryn Lores, PhD, discusses the CATHARSIS trial and the potential benefit of integrating brain-gut behavioral therapy into treatment for patients with Crohn’s disease.
000
www.GastroToday.com @gastrotoday.bsky.social · 19/02/2026
#GLP1 receptor agonists may be a safe and beneficial option for managing #obesity and metabolic comorbidities for adults with #InflammatoryBowelDisease. #GISky #IBDSky
docwirenews.com
Tolerability of GLP-1 RAs in IBD | Docwire News
For patients with IBD, GLP-1 receptor agonists provided benefits in weight loss and metabolic improvements without exacerbating IBD symptoms.
020
www.GastroToday.com @gastrotoday.bsky.social · 13/02/2026
A novel innovative virus-hunter #vaccine demonstrated the ability to actively capture viruses and overcome the tolerogenic immune microenvironment that is present with #HepatitisB virus infection. #HBV #HepatitisBVirus
docwirenews.com
Virus-Hunter Vaccine Shows Promise in Mice for Chronic HBV Infection | Docwire News
In chronic HBV carrier mice, SHARP vaccine variants showed promise toward durable viral control.
052
www.GastroToday.com @gastrotoday.bsky.social · 12/02/2026
AI-driven increases in nonadvanced adenoma detection during #Colonoscopy may meaningfully increase surveillance burden with unclear long-term benefit. #GISky #ColorectalCancer #ArtificialIntelligence
docwirenews.com
Surveillance Burden of Colonoscopy AI Polyp Detection | Docwire News
A retrospective analysis suggests that AI polyp detection during colonoscopy may improve adenoma detection but increase colonoscopy burden without long-term benefit.
000
www.GastroToday.com @gastrotoday.bsky.social · 10/02/2026
Real-world data presented at #CCCongress26 suggest IV and SC #vedolizumab have similar overall safety and efficacy in IBD, but IV use was linked to higher hospitalization and steroid use (#UlcerativeColitis) and higher shock rates (#CrohnsDisease). #IBDSky #GISky
docwirenews.com
IV vs SC Vedolizumab for IBD | Docwire News
While intravenous and subcutaneous vedolizumab had largely similar safety and efficacy for IBD, there were a few key differences in outcomes.
010
www.GastroToday.com @gastrotoday.bsky.social · 07/02/2026
Phase 1b data suggest early efficacy signals for APL-1401, a first-in-class DBH inhibitor, in moderate-to-severe #UlcerativeColitis. Results presented at the #CCCongress26 support further dose evaluation. #GISky #IBDSky
docwirenews.com
DBH Inhibitor for Ulcerative Colitis | Docwire News
In results from a phase 1b trial, dopamine beta-hydroxylase inhibitor, APL-1401, demonstrated early efficacy signals for patients with moderate-to-severe active ulcerative colitis.
010
www.GastroToday.com @gastrotoday.bsky.social · 05/02/2026
Early CATHARSIS trial data presented at #CCCongress26 suggest combining biologics with structured #BrainGut behavioral therapy may improve well-being in moderate-severe #CrohnsDisease. High feasibility, satisfaction, and retention reported. #IBDSky #GISky
docwirenews.com
CATHARSIS Meets Measures for Continuation | Docwire News
With successful randomization, masking, and retention, the CATHARSIS trial has proved it warrants continuation.
000
www.GastroToday.com @gastrotoday.bsky.social · 03/02/2026
Phase 1 data presented at #CCCongress26 highlight ATH-063, a first-in-class oral G9a inhibitor. In healthy volunteers, it showed favorable PK, no safety signals, and strong FoxP3+ Treg activation—supporting further study in biologics-resistant IBD. #IBDSky #GISky
docwirenews.com
Novel G9a-Inhibitor Shows Promise | Docwire News
According to data presented at the 2026 Crohn’s and Colitis Congress, ATH-063 showed preliminary potential with a favorable pharmacokinetics profile.
000